Trial Profile
A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARAMEL
- 01 Aug 2023 Results published in the American Journal of Hematology
- 18 Aug 2020 Status changed from active, no longer recruiting to completed.
- 04 Apr 2019 Planned End Date changed from 30 May 2019 to 9 Oct 2019.